tisotumab vedotin

DRUG10 trials

Sponsors

Seagen Inc., Seagen, a wholly owned subsidiary of Pfizer, Genmab, Zai Lab (Shanghai) Co., Ltd., Merck Sharp & Dohme LLC

Conditions

Bladder CancerCarcinoma, Non-Small-Cell LungCarcinoma, Squamous Cell of Head and NeckCervical CancerCervix CancerColorectal NeoplasmsEndometrium CancerEsophagus Cancer

Phase 1

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

TerminatedNCT03786081

Seagen, a wholly owned subsidiary of PfizerCervical Cancer

Start: 2019-02-27End: 2026-03-19Updated: 2026-07-22

A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies

CompletedNCT03913741

GenmabSolid Tumor

Start: 2019-02-27End: 2021-10-30Updated: 2022-06-23

To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies

CompletedNCT05866354

Zai Lab (Shanghai) Co., Ltd.Solid Malignancies

Start: 2023-06-16End: 2023-11-02Updated: 2023-11-27

Phase 2

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

CompletedNCT03245736

Seagen Inc.Bladder Cancer, Cervix Cancer, Endometrium Cancer +5

Start: 2017-08-23End: 2019-01-10Updated: 2021-11-04

A Trial of Tisotumab Vedotin in Cervical Cancer

CompletedNCT03438396

Seagen Inc.Cervical Cancer

Start: 2018-06-12End: 2022-08-02Updated: 2023-07-25

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruitingNCT03485209

Seagen, a wholly owned subsidiary of PfizerCarcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Colorectal Neoplasms +1

Start: 2018-06-25End: 2027-03-31Updated: 2026-07-22

A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

CompletedNCT03657043

Seagen Inc.Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer

Start: 2019-03-20End: 2022-02-08Updated: 2023-05-06

Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva

Not yet recruitingNCT07672782

GOG FoundationRecurrent or Metastatic Vulvar Cancer, Squamous Cell Carcinoma Vulva, Vulvar Carcinoma

Start: 2026-11-01End: 2029-12-01Target: 28Updated: 2026-06-29

Phase 3

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

CompletedNCT04697628

Seagen, a wholly owned subsidiary of PfizerCervical Cancer

Start: 2021-02-22End: 2026-01-15Updated: 2026-02-24

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Active, not recruitingNCT06459180

Merck Sharp & Dohme LLCCervical Cancer

Start: 2024-07-24End: 2028-06-15Target: 686Updated: 2026-08-28

Related Papers

Molecular Profiling of Tisotumab Vedotin–Treated Patients Identifies Immune Pathways Associated With Clinical Activity

Clinical Cancer Research2026-07-17

Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin.

2025-10-03

TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of physician’s choice as second-line treatment for recurrent or metastatic cervical cancer.

Journal of Clinical Oncology2025-05-28

The PRL3-zumab paradigm: A multicenter, single-dose-level phase 2 basket clinical trial design of an unconventional cancer immunotherapy.

2025-05-08

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

New England Journal of Medicine2024-07-03111 citations

Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C.

Journal of Clinical Oncology2024-06-0112 citations

Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301.

Journal of Clinical Oncology2024-06-012 citations

237 InnovaTV 301/ENGOT-Cx12/GOG-3057: a global, randomized, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in 2L Or 3L recurrent or metastatic cervical cancer

2024-03-011 citations

681 innovaTV 207 Parts E and F: a phase 2 study of tisotumab vedotin in patients with head and neck squamous cell carcinoma (trial in progress)

Regular and Young Investigator Award Abstracts2023-10-311 citations

Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study

Journal of Clinical Oncology2023-08-3167 citations

Abstract CT164: Tisotumab vedotin (TV) in squamous cell carcinoma of head and neck (SCCHN): interim analysis from innovaTV 207

Cancer Research2023-04-148 citations

Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205.

Journal of Clinical Oncology2022-06-0121 citations

Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC).

Journal of Clinical Oncology2022-06-016 citations

innovaTV 207: New combination dosing cohorts in the open label phase 2 study of tisotumab vedotin in solid tumors.

Journal of Clinical Oncology2022-06-015 citations

EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress)

E-Posters2021-11-012 citations

O013/#573 Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (R/MCC): phase 1B/2 engot-CX8/GOG-3024/innovaTV 205 study dose-escalation results

2021-11-011 citations

40 InnovaTV 301/ENGOT-cx12/GOG-3057: tisotumab vedotin vs investigator’s choice chemo in second- or third-line recurrent or metastatic cervical cancer

Cervical cancer2021-10-01

Tisotumab vedotin versus investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG 3057, trial in progress).

Journal of Clinical Oncology2021-05-204 citations

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.

2021-04-09281 citations

617 Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death

Regular and Young Investigator Award Abstracts2020-11-018 citations

6 more papers not shown